Refine
Has Fulltext
- yes (39)
Is part of the Bibliography
- yes (39)
Document Type
- Journal article (24)
- Conference Proceeding (9)
- Preprint (6)
Keywords
- Positronen-Emissions-Tomografie (21)
- PET (19)
- positron emission tomography (12)
- neuroendocrine tumor (6)
- 18F-FDG (5)
- SPECT (5)
- SSTR (5)
- PET/CT (4)
- PRRT (4)
- RADS (4)
- prostate cancer (4)
- theranostics (4)
- 18F-DCFPyL (3)
- 18F-LMI1195 (3)
- DaTscan (3)
- PSMA (3)
- Prostate Cancer (3)
- ageing (3)
- somatostatin receptor (3)
- vandetanib (3)
- 11C-HED (2)
- 123I-mIBG (2)
- 123I-metaiodobenzylguanidine (2)
- 18F-FDS (2)
- ECG (2)
- Ioflupane (2)
- Myokarditis (2)
- Neuroendocrine Tumor (2)
- PSMA-PET (2)
- PSMA-RADS (2)
- Parkinson (2)
- Parkinson Disease (2)
- Parkinson-Krankheit (2)
- Positron Emission Tomography (2)
- Stammzelle (2)
- TKI (2)
- Virchow Node (2)
- [177Lu]-DOTATATE/-DOTATOC (2)
- [68Ga] (2)
- cardiomyocytes (2)
- fatty acid (2)
- hiPSC-CM (2)
- induced pluripotent stem cells (2)
- medullary thyroid carcinoma (2)
- molecular imaging (2)
- myocardial sympathetic innervation imaging (2)
- myocarditis (2)
- peptide receptor radionuclide therapy (2)
- personalized medicine (2)
- personalized treatment (2)
- precision medicine (2)
- prostate-specific membrane antigen (2)
- stem cell therapy (2)
- tracer (2)
- tumor heterogeneity (2)
- tyrosine kinase inhibitor (2)
- 11C-Hydroxyephedrine (1)
- 11C-hydroxyephedrine (1)
- 123I-Ioflupane (1)
- 177Lu-DOTATATE (1)
- 177Lu-DOTATOC (1)
- 18F-DCFPL (1)
- 18F-flurpiridaz (1)
- 18FFBnTP (1)
- 2- deoxy-2-(18F)fluoro-D-glucose (1)
- 2-deoxy-2-(18F)fluoro-D-glucose (1)
- 2-deoxy-2-18F-fluoro-D-sorbitol (1)
- 68Ga-DOTANOC (1)
- 68Ga-DOTATATE (1)
- 68Ga-DOTATATE/-TOC (1)
- 68Ga-DOTATOC (1)
- 99mTc-DTPA (1)
- AI (1)
- Antidepressants (1)
- CXCR4 (1)
- DCGAN (1)
- DOTATOC (1)
- Diabetes (1)
- ECG-gated (1)
- EKG (1)
- FV45 (1)
- GAN (1)
- GI (1)
- Ganglia (1)
- Gastrointestinal (1)
- Glomerular filtration (1)
- HFmrEF (1)
- Herz (1)
- ICD (1)
- Imaging pitfalls (1)
- MDD (1)
- MI-RADS (1)
- MIBG (1)
- MPI (1)
- MRI (1)
- Magnetresonanztomografie (1)
- Medullärer Schilddrüsenkrebs (1)
- Metaiodobenzylguanidine (1)
- Neuroendocrine (1)
- Nierenfunktionsstörung (1)
- Oncology (1)
- PROMISE (1)
- PSMA-RADS-3A (1)
- PSMA-RADS-3B (1)
- PSMA-targeted PET (1)
- Pancreas (1)
- Parkinsonism (1)
- Parkinson’s disease (1)
- Pitfall (1)
- Positron-Emission Tomography (1)
- Positronenemissionstomografie (1)
- Prostata (1)
- Radionuclide Therapy (1)
- Radiotracer (1)
- SPECT/CT (1)
- SSTR-PET (1)
- SSTR-RADS (1)
- Single-Photon-Emissions-Computertomographie (1)
- Standardisierung (1)
- Tracer (1)
- ZDF rats (1)
- [68Ga]DOTATOC (1)
- [\(^{68}\)Ga]Pentixafor (1)
- \(^{18}\)F-FDG (1)
- \(^{18}\)F-fluorodeoxyglucose (1)
- angiotensin II type 1 receptor (1)
- antidepressant (1)
- antidepressants (1)
- arrhythmia (1)
- artificial intelligence (1)
- autonomic nervous system (1)
- cardiac (1)
- cardiac innervation imaging (1)
- cardiac nerve (1)
- cardiac sympathetic nerve system (1)
- cardiac sympathetic nervous system (1)
- chemokine receptor (1)
- coronary artery disease (1)
- depression (1)
- diabetes (1)
- diabetic cardiomyopathy (1)
- diabetische Kardiomyopathie (1)
- heart (1)
- heart failure (1)
- heart failure with mid-range ejection fraction (1)
- hydroxyephedrine (1)
- inflammation (1)
- interobserver (1)
- interreader (1)
- kidney (1)
- mIBG (1)
- machine learning (1)
- magnetic resonance imaging (1)
- major depressive disorder (1)
- moycardial sympathetic innervation (1)
- myocardial nerve (1)
- myocardial perfusion imaging (1)
- neuroendocrine neoplasia (1)
- pancreas (1)
- phaeochromocytoma (1)
- prostate-specific membrane antigen (PSMA) (1)
- quantification (1)
- renal failure (1)
- renal imaging (1)
- renin-angiotensin system (1)
- reporting and data system (1)
- reporting and data systems (1)
- single photon emission computed tomography: sympathetic nerve (1)
- somatostatin receptor (SSTR) (1)
- split renal function (1)
- standardization (1)
- standardized reporting (1)
- storage vesicle turnover (1)
- stroke (1)
- sympathetic nerve (1)
- sympathetic nervous system (1)
- unilateral ureteral obstruction (1)
- valsartan (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (39)
- Medizinische Klinik und Poliklinik I (6)
- Medizinische Klinik und Poliklinik II (5)
- Institut für Anatomie und Zellbiologie (4)
- Institut für Pharmakologie und Toxikologie (2)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (2)
- Institut für Pharmazie und Lebensmittelchemie (1)
- Pathologisches Institut (1)
Sonstige beteiligte Institutionen
- Johns Hopkins School of Medicine (18)
- Johns Hopkins University School of Medicine (5)
- Johns Hopkins School of Medicine, Baltimore, MD, U.S. (4)
- Department of Biomedical Imaging, National Cerebral and Cardiovascular Research Center, Suita, Japan (2)
- Division of Medical Technology and Science, Department of Medical Physics and Engineering, Course of Health Science, Osaka University Graduate School of Medicine, Suita Japan (2)
- Institut for Molecular Biology and CMBI, Department of Genomics, Stem Cell Biology and Regenerative Medicine, Leopold-Franzens-University Innsbruck, Innsbruck, Austria (2)
- Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Science, Baltimore, MD, USA (2)
- Department of Nuclear Medicine, Kanazawa University (1)
- Hospital Augsburg, Augsburg, Germany (1)
- Johns Hopkins Medicine (1)
EU-Project number / Contract (GA) number
- 701983 (39) (remove)
Standardized reporting is more and more routinely implemented in clinical practice and such structured reports have a major impact on a large variety of medical fields, e.g. laboratory medicine, pathology, and, recently, radiology. Notably, the field of nuclear medicine is constantly evolving, as novel radiotracers for numerous clinical applications are developed. Thus, framework systems for standardized reporting in this field may a) increase clinical acceptance of new radiotracers, b) allow for inter- and intra-center comparisons for quality assurance, and c) may be used in (global) multi-center studies to ensure comparable results and enable efficient data abstraction. In the last two years, several standardized framework systems for positron emission tomography (PET) radiotracers with potential theranostic applications have been proposed. These include systems for prostate-specific membrane antigen (PSMA)-targeted PET agents for the diagnosis and treatment of prostate cancer (PCa) and somatostatin receptor (SSTR)-targeted PET agents for the diagnosis and treatment of neuroendocrine neoplasias. In the present review, those standardized framework systems for PSMA- and SSTR-targeted PET will be briefly introduced followed by an overview of their advantages and limitations. In addition, potential applications will be defined, approaches to validate such concepts will be proposed, and future perspectives will be discussed.